Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 3 days ago Drug news

FDA accepts Mylan's BLA for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim).- Mylan + Biocon Ltd

Mylan N.V. and Biocon Ltd. announced that the FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed...

Added 4 days ago Drug news

NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche

The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...

Added 5 days ago Drug news

UK NICE rejects the use of Kanuma (sebelipase alfa) to treat lysosomal acid lipase deficiency- Alexion

The UK's National Institute for Health and Care Excellence has published its a final evaluation which rejects the use of...

View all news articles


Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation



Non-Hodgkin’s lymphoma: diagnosis and management: NICE Guidelines

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over.

Added 4 months ago

NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

CLL remains the most prevalent adult lerkemia in Wester countries but is considered rare in regions such as East Asia. CLL/SLL comprises approximately 7% of newly diagnosed cases of NHL.

Added 4 months ago

Multiple Myeloma: ESMO Clinical Practice Guidelines

The ESMO Clinical Practice Guideline in multiple myeloma, which accounts for approximately 10% of all haematological malignancies, covers recommendations for diagnosis; staging and risk assessment...

Added 4 months ago

View all guidelines

Journal articles

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with age and varies

Added 11 hours ago

Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Standard criteria for toxicity and for response to treatment are important prerequisites to the conduct of cancer trials. The Eastern Cooperative Oncology Group criteria for toxicity and...

Added 13 hours ago

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

To complete the existing treatment guidelines for all tumor types, ESMO organizes consensus conferences to better clarify open issues in each disease. In this setting, a consensus conference on the...

Added 13 hours ago

View all journal articles